መነሻ › አኩት ማይሎይድ ሊውኬሚያ › New York › Rochester
በRochester፣ NY ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች
ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ 16 ጥናቶች በRochester እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።
Official study text (English)
ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ተሳታዮችን በመፈለግ ላይደረጃ 2
- Rochester General Hospital, Rochester
- University of Rochester, Rochester
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
ተሳታዮችን በመፈለግ ላይደረጃ 2
- University of Rochester, Rochester
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
ተሳታዮችን በመፈለግ ላይደረጃ 3
- University of Rochester Medical Center, Rochester
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
ተሳታዮችን በመፈለግ ላይደረጃ 2
- University of Rochester, Rochester
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
ተሳታዮችን በመፈለግ ላይደረጃ 2
- University of Rochester, Rochester
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
ተሳታዮችን በመፈለግ ላይደረጃ 2
- University of Rochester, Rochester
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
ተሳታዮችን በመፈለግ ላይደረጃ 3
- University of Rochester, Rochester
A Telehealth Advance Care Planning Intervention
ተሳታዮችን በመፈለግ ላይ
- University of Rochester, Rochester
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
ተሳታዮችን በመፈለግ ላይደረጃ 1
- Wilmot Cancer Institute, University of Rochester, Rochester
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
ተሳታዮችን በመፈለግ ላይደረጃ 3
- University of Rochester Medical Center (URMC), Rochester
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
- Strong Memorial Hospital/University of Rochester, Rochester
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
ተሳታዮችን በመፈለግ ላይ
- University of Rochester Medical Center, Rochester
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
ተሳታዮችን በመፈለግ ላይየመጀመሪያ ደረጃ 1
- Wilmot Cancer Institute, University of Rochester, Rochester
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
- The University of Rochester, Rochester
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
- University of Rochester Medical Center, Rochester
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
ተሳታዮችን በመፈለግ ላይጤናማ ተሳታዮች ይቀበላሉ
- University of Rochester, Rochester
በሌሎች ከተሞች ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ጥናቶች
- Houston, TX85 ጥናቶች
- New York City, NY51 ጥናቶች
- Boston, MA44 ጥናቶች
- Seattle, WA41 ጥናቶች
- Baldwin Park, CA40 ጥናቶች
- Columbus, OH35 ጥናቶች
- Philadelphia, PA34 ጥናቶች
- Durham, NC33 ጥናቶች
- Atlanta, GA31 ጥናቶች
- Tampa, FL29 ጥናቶች
- Chicago, IL26 ጥናቶች
- Portland, OR25 ጥናቶች
በRochester ውስጥ ያሉ ሌሎች ጥናቶች
- የሳንባ ካንሰር15 ጥናቶች
- የጡንቻ ካንሰር15 ጥናቶች
- ካንሰር (ሁሉም ዓይነቶች)14 ጥናቶች
- ከባድ ሰውነት14 ጥናቶች
- ከመጠን በላይ ክብደት13 ጥናቶች
- ኖን-ስማል ሴል የሳንባ ካንሰር13 ጥናቶች
- የፕሮስቴት ካንሰር10 ጥናቶች
- Metastatic Cancer8 ጥናቶች
- Multiple Myeloma8 ጥናቶች
- የሽንት ፊኛ ካንሰር7 ጥናቶች
- ማዮቶኒክ ዲስትሮፊ7 ጥናቶች
- የፓንክሪያስ ካንሰር7 ጥናቶች
ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።